Anuradha Dube Selected Research

Visceral Leishmaniasis (Kala Azar)

7/2022	Combined immunotherapeutic effect of Leishmania-derived recombinant aldolase and Ambisome against experimental visceral leishmaniasis.
5/2022	Leishmania donovani secretory protein nucleoside diphosphate kinase b localizes in its nucleus and prevents ATP mediated cytolysis of macrophages.
1/2021	Status of IL-4 and IL-10 driven markers in experimental models of Visceral Leishmaniasis.
1/2021	A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis.
8/2020	Preventive as well as therapeutic significances of linoleic acid in the containment of Leishmania donovani infection.
1/2020	Parasitic load determination by differential expressions of 5-lipoxygenase and PGE2 synthases in visceral leishmaniasis.
12/2019	Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.
1/2019	Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of Leishmania (Leishmania) donovani.
1/2019	Prophylactic interferon-γ and interleukin-17 facilitate parasite clearance in experimental visceral leishmaniasis.
1/2018	Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anuradha Dube Research Topics

Disease

60	Visceral Leishmaniasis (Kala Azar) 07/2022 - 11/2004
18	Infections 01/2021 - 11/2004
16	Leishmaniasis 01/2021 - 12/2004
4	Hypersensitivity (Allergy) 01/2017 - 10/2008
3	Parasitic Diseases (Parasitic Disease) 07/2022 - 01/2019
3	Communicable Diseases (Infectious Diseases) 01/2019 - 01/2013
2	Hemolysis 12/2017 - 12/2017
1	Acquired Immunodeficiency Syndrome (AIDS) 05/2022
1	Disease Progression 01/2021
1	Malnutrition (Nutritional Deficiencies) 08/2020
1	Body Weight (Weight, Body) 03/2020
1	Coinfection 08/2015
1	Reinfection 01/2014
1	Tuberculosis (Tuberculoses) 04/2013
1	Pulmonary Tuberculosis 04/2013
1	Leprosy (Hansen's Disease) 04/2013
1	Mycoses (Diseases, Fungus) 03/2012
1	Necrosis 02/2012

Drug/Important Bio-Agent (IBA)

21	VaccinesIBA 05/2022 - 03/2006
15	Amphotericin B (Amphotericin)FDA LinkGeneric 12/2017 - 07/2007
14	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2006
9	Pharmaceutical PreparationsIBA 05/2022 - 12/2004
6	AntigensIBA 01/2021 - 03/2006
6	ChitosanIBA 12/2017 - 01/2011
5	CytokinesIBA 01/2021 - 02/2012
5	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2015 - 01/2011
5	NanocapsulesIBA 08/2015 - 11/2012
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2017 - 10/2005
4	Interleukin-12 (IL 12)IBA 02/2012 - 10/2008
3	Interleukin-10 (Interleukin 10)IBA 01/2021 - 01/2012
3	Interleukin-4 (Interleukin 4)IBA 01/2021 - 01/2012
3	LipidsIBA 03/2012 - 07/2007
3	Immunoglobulin G (IgG)IBA 01/2012 - 10/2008
2	EnzymesIBA 05/2022 - 01/2014
2	Biological ProductsIBA 01/2019 - 12/2013
2	InterferonsIBA 01/2019 - 02/2012
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2017 - 02/2012
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2017 - 01/2005
2	LigandsIBA 12/2015 - 11/2012
2	gluconic acid (gluconate)FDA LinkGeneric 08/2015 - 04/2009
2	AntimonyIBA 08/2015 - 04/2009
2	SodiumIBA 08/2015 - 04/2009
2	NAD (NADH)IBA 04/2015 - 03/2015
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 10/2014 - 04/2013
2	GelatinIBA 05/2014 - 02/2010
2	Protein Disulfide-IsomerasesIBA 01/2014 - 01/2012
2	Liposomes (Liposome)IBA 03/2012 - 03/2006
1	liposomal amphotericin B FDA Link 07/2022
1	Fructose-Bisphosphate Aldolase (Aldolase)IBA 07/2022
1	Purinergic P2X7 ReceptorsIBA 05/2022
1	Adenosine Triphosphate (ATP)IBA 05/2022
1	Interleukin-13IBA 01/2021
1	Linoleic Acid (Linoleate)IBA 08/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 08/2020
1	Uric Acid (Urate)IBA 03/2020
1	Glucose (Dextrose)FDA LinkGeneric 03/2020
1	Alkaline PhosphataseIBA 03/2020
1	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 01/2020
1	Dinoprostone (PGE2)FDA Link 01/2020
1	EicosanoidsIBA 01/2020
1	Vaccine AdjuvantsIBA 12/2019
1	InterleukinsIBA 01/2019
1	Interleukin-17 (Interleukin 17)IBA 01/2019
1	Polysorbates (PSML)FDA Link 12/2017
1	SuspensionsIBA 12/2017
1	MicellesIBA 12/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017
1	calcium phosphateIBA 11/2016
1	GalactosamineIBA 12/2015
1	ChondroitinIBA 08/2015
1	Mannose (D-Mannose)IBA 08/2015
1	glycol-chitosanIBA 05/2015
1	StearatesIBA 05/2015
1	AlginatesIBA 05/2015
1	lipoteichoic acidIBA 04/2015
1	ChaperoninsIBA 04/2015
1	tryparedoxin peroxidaseIBA 04/2015
1	LactoferrinIBA 01/2015
1	Lipid NanoparticlesIBA 10/2014
1	LectinsIBA 06/2014
1	Mitogen Receptors (Mitogen Receptor)IBA 06/2014
1	trypanothione reductaseIBA 03/2014
1	IsomerasesIBA 01/2014
1	Phosphates (Orthophosphate)IBA 01/2014
1	Mycobacterium w vaccineIBA 04/2013
1	Immunologic Factors (Immunomodulators)IBA 04/2013
1	Biomarkers (Surrogate Marker)IBA 01/2013
1	PhosphatidylserinesIBA 11/2012
1	AminopeptidasesIBA 05/2012
1	Methionine (L-Methionine)FDA Link 05/2012
1	tripalmitinIBA 03/2012
1	miltefosine (Impavido)IBA 02/2012
1	Transforming Growth Factors (Transforming Growth Factor)IBA 02/2012
1	Triose-Phosphate Isomerase (Triosephosphate Isomerase)IBA 01/2012
1	MannansIBA 02/2011
1	1,4-dihydropyridine (dihydropyridine)IBA 07/2010
1	DNA VaccinesIBA 07/2009

Therapy/Procedure

11	Drug Therapy (Chemotherapy) 01/2021 - 11/2004
9	Therapeutics 07/2022 - 12/2004
3	Immunotherapy 01/2021 - 10/2014